Topic
Immunology
IL-23, IL-17, JAK, TNF inhibitors, biologic access, payer coverage, step therapy, and immunology drug comparison.
Pricing & Access· May 19, 2026 · 15 min read
Humira coverage guide: formulary, biosimilar landscape, prior authorization, and patient assistance
Humira (adalimumab) was once the world's best-selling drug, but its access landscape has transformed. With ten biosimilars now FDA-approved and all three major PBMs...
By Ran Chen#Immunology#Prior Authorization#Payer Policy
Pricing & Access· May 19, 2026 · 17 min read
Rinvoq vs Humira: label, access, and payer coverage compared
Rinvoq (upadacitinib) and Humira (adalimumab) represent two fundamentally different approaches to treating rheumatoid arthritis, psoriatic arthritis, and other...
By Ran Chen#Immunology#Prior Authorization#Payer Policy
Pricing & Access· May 19, 2026 · 11 min read
Skyrizi vs Stelara: label, access, and payer coverage compared
Skyrizi (risankizumab) and Stelara (ustekinumab) are both IL-23 pathway inhibitors used in plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis...
By Ran Chen#Immunology#Prior Authorization#Payer Policy
Pricing & Access· May 18, 2026 · 13 min read
Rinvoq coverage guide: formulary, prior authorization, JAK safety requirements, and patient assistance
Rinvoq (upadacitinib) is a JAK1 inhibitor approved for nine immune-mediated indications including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis,...
By Ran Chen#Immunology#Prior Authorization#Payer Policy
Pricing & Access· May 18, 2026 · 11 min read
Stelara coverage guide: formulary, prior authorization, biosimilar landscape, and patient assistance
Stelara (ustekinumab) is an IL-12/23 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. With nine biosimilars now...
By Ran Chen#Immunology#Prior Authorization#Payer Policy
